<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="15369"><DrugName>MLN-2201</DrugName><DrugSynonyms><Name><Value>LDP-01</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MLN-01</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MLN-2201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anti-beta2-integrin MAb, LeukoSite</Value></Name></DrugSynonyms><CompanyOriginator id="27414">LeukoSite Inc</CompanyOriginator><CompaniesSecondary><Company id="20954">XOMA Corp</Company><Company id="21991">Takeda Oncology</Company><Company id="27414">LeukoSite Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15369" type="Drug"><TargetEntity id="257899" type="siDrug">LDP-01</TargetEntity></SourceEntity><SourceEntity id="20954" type="Company"><TargetEntity id="5037133783" type="organizationId">XOMA Corp</TargetEntity></SourceEntity><SourceEntity id="21991" type="Company"><TargetEntity id="4295907189" type="organizationId">Millennium Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="27414" type="Company"><TargetEntity id="5001538214" type="organizationId">LeukoSite Inc</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"></TargetEntity><TargetEntity id="D006084" type="MeSH"></TargetEntity><TargetEntity id="1133" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2591" type="Action"><TargetEntity id="875" type="Mechanism">Integrin Receptor Antagonists</TargetEntity><TargetEntity id="3275" type="Mechanism">Anti-Integrin</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="515">Transplant rejection</Indication><Indication id="65">Stroke</Indication></IndicationsSecondary><ActionsPrimary><Action id="2591">Integrin antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1596">Immunomodulator</Action><Action id="2659">Cardioprotectant</Action><Action id="2660">Vasoprotectant</Action></ActionsSecondary><Technologies><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2017-08-18T05:09:22.000Z</LastModificationDate><ChangeDateLast>2008-07-09T11:26:05.000Z</ChangeDateLast><AddedDate>1997-06-19T15:31:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Millennium (formerly LeukoSite) and XOMA were developing the anti-integrin monoclonal antibody &lt;ulink linkID="15369" linkType="Drug"&gt;MLN-2201&lt;/ulink&gt; (formerly MLN-01 and LDP-01) for the potential treatment of vascular inflammation indications [&lt;ulink linkID="430701" linkType="reference"&gt;430701&lt;/ulink&gt;]. By January 2002, the drug was undergoing phase I trials for prevention of post-ischemic reperfusion injury after stroke [&lt;ulink linkID="413097" linkType="reference"&gt;413097&lt;/ulink&gt;], [&lt;ulink linkID="423719" linkType="reference"&gt;423719&lt;/ulink&gt;], [&lt;ulink linkID="427477" linkType="reference"&gt;427477&lt;/ulink&gt;], [&lt;ulink linkID="435619" linkType="reference"&gt;435619&lt;/ulink&gt;]. In June 2003, phase I trials were also underway in conditions related to inflammation of the heart and blood vessels [&lt;ulink linkID="494117" linkType="reference"&gt;494117&lt;/ulink&gt;]. However, in October 2003, development had been discontinued due to the failure of phase I trial results to meet predefined criteria for further development [&lt;ulink linkID="508449" linkType="reference"&gt;508449&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The open-label, dose-escalating trial, initiated in June 2003, was to test &lt;ulink linkID="15369" linkType="Drug"&gt;MLN-2201&lt;/ulink&gt; administered as a single iv infusion to healthy volunteers [&lt;ulink linkID="494117" linkType="reference"&gt;494117&lt;/ulink&gt;]. Based on preliminary phase I results released in October 2003, Xoma made the decision to terminate this program and direct its resources towards more promising products [&lt;ulink linkID="508449" linkType="reference"&gt;508449&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Prior to its merger with Millennium, LeukoSite had been developing &lt;ulink linkID="15369" linkType="Drug"&gt;MLN-2201&lt;/ulink&gt; for the potential prevention of kidney rejection as well as stroke [&lt;ulink linkID="250975" linkType="reference"&gt;250975&lt;/ulink&gt;], [&lt;ulink linkID="274580" linkType="reference"&gt;274580&lt;/ulink&gt;]. In January 1999, LeukoSite reported that the drug was being tested in phase I/IIa trials involving kidney transplant and stroke patients [&lt;ulink linkID="310554" linkType="reference"&gt;310554&lt;/ulink&gt;]. However, since the merger in early 2000, Millennium has not reported on this additional indication.&lt;/para&gt;&lt;para&gt;By 1997, pharmacology and safety studies in nonhuman primates had been completed. At this time, LeukoSite signed up the &lt;ulink linkID="26274" linkType="Company"&gt;Therapeutic Antibody Centre&lt;/ulink&gt; for the manufacture of the antibody allowing a clinical study to be initiated [&lt;ulink linkID="274580" linkType="reference"&gt;274580&lt;/ulink&gt;]. By 1999, it was reported that the &lt;ulink linkID="26274" linkType="Company"&gt;Therapeutic Antibody Centre&lt;/ulink&gt; sponsored clinical trial showed that &lt;ulink linkID="15369" linkType="Drug"&gt;MLN-2201&lt;/ulink&gt; inhibited the recruitment of leukocytes into inflamed tissue [&lt;ulink linkID="315156" linkType="reference"&gt;315156&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="15369" linkType="Drug"&gt;MLN-2201&lt;/ulink&gt; is a humanized anti-integrin monoclonal antibody that blocks the recruitment of leukocytes. It selectively inhibits beta-2 integrin function while reducing the potential to impair the normal functions of beta-2 integrin involved in fighting infection [&lt;ulink linkID="274580" linkType="reference"&gt;274580&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="21991">Takeda Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-10T00:00:00.000Z</StatusDate><Source id="508449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20954">XOMA Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-10T00:00:00.000Z</StatusDate><Source id="508449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21991">Takeda Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-10T00:00:00.000Z</StatusDate><Source id="508449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20954">XOMA Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-10T00:00:00.000Z</StatusDate><Source id="508449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21991">Takeda Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-10-10T00:00:00.000Z</StatusDate><Source id="508449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20954">XOMA Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-11-27T00:00:00.000Z</StatusDate><Source id="430701" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20954">XOMA Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-11-27T00:00:00.000Z</StatusDate><Source id="430701" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27414">LeukoSite Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-01-05T00:00:00.000Z</StatusDate><Source id="310554" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27414">LeukoSite Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-01-05T00:00:00.000Z</StatusDate><Source id="310554" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27414">LeukoSite Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-01-13T00:00:00.000Z</StatusDate><Source id="274580" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27414">LeukoSite Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-01-13T00:00:00.000Z</StatusDate><Source id="274580" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27414">LeukoSite Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-01-13T00:00:00.000Z</StatusDate><Source id="274580" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27414">LeukoSite Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-06-19T15:31:10.000Z</StatusDate><Source id="250975" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21991">Takeda Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-01-30T00:00:00.000Z</StatusDate><Source id="430701" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21991">Takeda Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-01-30T00:00:00.000Z</StatusDate><Source id="437649" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21991">Takeda Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-01-30T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21991">Takeda Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-01-05T00:00:00.000Z</StatusDate><Source id="310554" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21991">Takeda Oncology</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-01-05T00:00:00.000Z</StatusDate><Source id="310554" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01036"><Name>Integrin</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20954">XOMA Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="113751" title="XOMA to develop Millennium's MLN-2222 and MLN-2201 for vascular inflammation"></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>